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The in vitro antifungal susceptibility of 77 isolates belonging to different clinically relevant species of Aspergillus section Flavi,
including those of different phylogenetic clades of A. flavus, was tested for nine antifungal agents using a microdilution refer-
ence method (CLSI, M38-A2). Terbinafine and the echinocandins demonstrated lower MICs/MECs for all species evaluated, fol-
lowed by posaconazole. Amphotericin B showedMICs> 2g/ml for 38 (49.4%) of the 77 isolates tested.
Invasive aspergillosis is the most common cause of mortality re-sulting from infection by filamentous fungi in leukemic patients
and hematopoietic stem cell transplant (HSCT) recipients world-
wide (1). After Aspergillus fumigatus, A. flavus is the leading cause
of invasive and noninvasive aspergillosis, particularly in infections
of the respiratory tract, skin, mucosae, and eyes (2, 3). In contrast
to A. fumigatus, A. flavus rarely causes invasive pneumonia and
systemic infections in immunocompetent hosts (4). Voriconazole
(VRC) is currently the drug of choice for the treatment of asper-
gillosis, although lipid formulations of amphotericin B (AMB),
posaconazole (PSC), and caspofungin (CFG) have also been rec-
ommended to treat invasive aspergillosis refractory to or intoler-
ant to other therapies (5). Human infections by A. flavus usually
respond to treatment with AMB, VRC, and itraconazole (ITC),
although failures of these drugs in cases of aspergillosis have al-
ready been reported (6–8). Invasive human aspergillosis caused by
species of the section Flavi may involve several taxa, including A.
flavus, A. oryzae, A. tamarii, A. parasiticus, Petromyces alliaceus, A.
nomius, A. qizutongi, A. beijingensis, and A. novoparasiticus (3,
9–12). The high number of species of such a section that are po-
tentially pathogenic for humans and their morphological similar-
ity make it difficult to ascertain the clinical and epidemiological
peculiarities of the infections they cause. In addition, cryptic spe-
cies have been described within the taxon A. flavus, the most fre-
quent infecting species (13, 14). Using molecular tools, we re-
cently identified three phylogenetic species of A. flavus causing
infections in humans (14). Considering that the antifungal sus-
ceptibility profiles of the members of the section Flavi are not
completely known, in the present study, we evaluated the in vitro
activity of nine antifungal drugs against 77 isolates representative
of clinically relevant species, including A. flavus (belonging to our
clades I, II, and III) (14), A. oryzae (belonging to our A. oryzae
group) (14), A. parasiticus, A. tamarii, and A. novoparasiticus
(Table 1).
The isolateswere cultured onpotato dextrose agar (PDA;Difco
Laboratories, Detroit, MI) and incubated at 25°C for 7 days to
prepare the fungal inocula. Paecilomyces variotii ATCC 36257,
Candida parapsilosis ATCC 22019, and Candida krusei ATCC
6258 were included as control organisms. The isolates were previ-
ously identified by sequencing the acetamidase (amdS) and O-
methyltransferase (omtA) genes and the internal transcribed
spacer (ITS) region of ribosomal DNA (rDNA) (14, 15). Antifun-
gal susceptibility testing was performed according to the Clinical
and Laboratory Standards Institute (CLSI)M38-A2 protocol (16).
Briefly, 100-l culture preparations in RPMI 1640 with 2% glu-
cose were inoculated into the flat-bottom wells of 96-well micro-
titer plates containing 100 l of the drug dilutions. The final in-
oculum concentration ranged from 0.4 104 to 5 104 CFU/ml.
The drugs tested were provided by the manufacturers as pure
powders and included the following: terbinafine (TRB), ITC,
VRC, PSC, AMB, anidulafungin (AFG),micafungin (MFG), CFG,
and 5-fluorocytosine (5FC). The MIC endpoints for the triazoles
andAMBwere defined as the lowest concentration that resulted in
complete growth inhibition, while that of 5FC was defined as the
lowest concentration that caused 50% growth inhibition. For the
echinocandins, we applied the minimum effective concentration
(MEC) endpoints, which were defined as the minimal antifungal
concentration that caused visible morphological alterations of the
hyphae. Tests were performed in duplicate, and when the results
did not concur, the test was repeated and the mode of the MICs
and MECs was considered.
The results are shown in Table 1. In general, TRB and the
echinocandins showed the lowest MICs/MECs for all species
tested. Terbinafine showed a total geometric mean (GM) MIC of
0.03g/ml, while AFG andMFG showed a total GMMEC of 0.03
g/ml. ForCFG, the total GMMECwas 0.07g/ml. Posaconazole
exhibited the lowest GM MIC among the azoles tested (0.35 g/
ml). Voriconazole and ITC showed a total GMMICof 0.60g/ml.
The three clades of A. flavus exhibited similar in vitro susceptibil-
ities to all drugs tested. Despite some numerical differences that
were observed among the MICs obtained with different triazoles,
the GM MICs were quite similar and mostly within double dilu-
tions, demonstrating the expected variability for the method. Re-
garding the other drugs evaluated, AMB exhibited MICs  2 for
38 (49.4%) of the 77 isolates tested, and 5FC showed poor in vitro
activity against all species tested (GMMIC 51.56 g/ml). ITC,
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TABLE 1 Activities of nine antifungal drugs against 77 isolates belonging to species of Aspergillus section Flavia
Species (no. of
isolates)
Antifungal
agentb
MICc or MECd (g/ml)
Range GM 50%/90% 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128
A. parasiticus (3) AMB 1–2 1.25 2 1
ITC 0.25–0.5 0.32 1 2
VRC 0.5 0.5 3
PSC 0.5–1 0.79 1 2
TRB 0.03 0.03 3
5FC 64 64 3
CFG 0.06 0.06 3
AFG 0.03 0.03 3
MFG 0.015 0.015 3
A. novoparasiticus (4) AMB 2–4 2.38 3 1
ITC 0.5–1 0.59 3 1
VRC 0.5–1 0.59 3 1
PSC 0.5 0.5 4
TRB 0.03 0.03 4
5FC 64 64 4
CFG 0.06–0.125 0.07 3 1
AFG 0.03 0.03 4
MFG 0.015–0.06 0.04 1 1 2
A. flavus clade I (26) AMB 1–2 1.31 1/2 16 10
ITC 0.25–1 0.44 0.5/1 7 17 2
VRC 0.25–0.5 0.47 0.5/0.5 2 24
PSC 0.5 0.50 0.5/0.5 26
TRB 0.03 0.03 0.030.03 26
5FC 8 to64 54.54 64/64 2 24
CFG 0.06–0.125 0.08 0.06/0.125 14 12
AFG 0.03–0.06 0.03 0.03/0.06 24 2
MFG 0.015–0.03 0.03 0.03/0.03 6 20
A. flavus clade II (12) AMB 1–2 1.19 1/2 9 3
ITC 0.5–1 0.71 0.5/1 6 6
VRC 0.5–2 0.71 0.5/1 7 4 1
PSC 0.25–0.5 0.45 0.5/0.5 2 10
TRB 0.03 0.03 0.03/0.03 12
5FC 64 to64 64 64/64 12
CFG 0.03–0.125 0.06 0.06/0.06 1 10 1
AFG 0.03 0.03 0.03/0.03 12
MFG 0.015–0.125 0.03 0.03/0.06 5 4 1 2
A. flavus clade III (20) AMB 1–4 1.62 2/2 7 12 1
ITC 0.25–2 0.96 1/2 2 2 11 5
VRC 0.25–2 0.84 1/2 2 4 11 3
PSC 0.25–1 0.45 0.5/1 5 13 2
TRB 0.03 0.03 0.03/0.03 20
5FC 64 to64 64 64/64 20
CFG 0.03–0.125 0.05 0.06/0.125 5 13 2
AFG 0.03–0.06 0.03 0.03/0.06 18 2
MFG 0.015–0.125 0.05 0.03/0.06 2 9 7 2
A. oryzae group (10) AMB 1–2 1.62 2/2 3 7
ITC 0.25–1 0.44 0.5/1 3 6 1
VRC 0.25–0.5 0.47 0.5/0.5 1 9
PSC 0.5 0.50 0.5/0.5 10
TRB 0.03 0.03 0.03/0.03 10
5FC 8 to64 51.98 64/64 1 9
CFG 0.06–0.125 0.08 0.06/0.125 5 5
AFG 0.03–0.06 0.03 0.03/0.03 9 1
MFG 0.015–0.03 0.03 0.03/0.03 2 8
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VRV, and PSC showed MICs between 1 and 4 g/ml for the two
isolates of A. tamarii.
The treatment of invasive aspergillosis is a challenge due to the
diagnostic difficulty, the severity of the clinical conditions of the
patients, and the limited number of antifungal drugs available (8).
Little is known about the prevalence of A. flavus and cryptic spe-
cies in clinical samples or their susceptibility to antifungal drugs.
One of the most interesting findings of this study was the demon-
stration that echinocandins generally exhibited higher in vitro ac-
tivity than triazoles and AMB against all species. In addition, no
differences in susceptibility were observed within the three A. fla-
vus clades. Otherwise, A. tamarii appears to be less susceptible to
azoles than other species of the section. Aspergillus tamarii has
been primarily described to cause sinusitis, keratitis, and onycho-
mycosis (11, 17, 18). In the case of azoles, the MICs of ITC and
VRC for all isolates were higher than that of PSC, which is in
agreement with other studies (19–21). Amphotericin B appears to
have limited activity against most species of the section Flavi. In
general, the AMB MIC values were at least 2-fold higher than
those obtained with isolates of the section Fumigati (22, 23). Lass-
Flörl et al. (24) correlated the in vitro antifungal susceptibility of
12 A. flavus strains isolated from bone marrow transplant recipi-
ents with their clinical outcome. Only the four patients infected
with susceptible isolates (AMB MIC 2 g/ml; n 4) survived,
while those with resistant isolates (AMB MIC 2 g/ml; n 8)
died. Despite showing excellent in vitro activity against some
strains of Aspergillus spp., the therapeutic efficacy of TRB in the
management of nondermatophytic mold infections is still unclear
at present (25).
In summary, there is a great diversity of species belonging to
the section Flavi that cause infections in humans. We emphasize
the importance of using molecular methods to accurately identify
Aspergillus at the species level because different speciesmay vary in
terms of susceptibility to antifungal agents.
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